March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
Faigh amach an eolaíocht taobh thiar de chóireáil teiripe CAR T Cell san India! Fiosraigh conas a chlaochlaíonn an chóireáil réabhlóideach seo do chealla imdhíonachta ina dtrodairí ailse. Léigh ár mblag anois chun tuilleadh a fhoghlaim faoin teiripe mhíorúilteach seo agus conas ..
Ar smaoinigh tú riamh an bhfuil bealach cumhachtach ann chun ailse a chomhrac? Anois samhlaigh má fuair tú gathanna dóchais lá amháin i do chomhrac in aghaidh na hailse, cóireáil a úsáideann cumhacht chóras imdhíonachta do choirp féin chun díriú ar...
Bealtaine 2023: D’othair aosach a bhfuil lymphoma ard-ghrád B-chealla (HGBL) acu, nach sonraítear a mhalairt (NOS), nó liomfóma B-chealla móra idirleata (DLBCL) nach bhfuair cóireáil roimhe seo agus a bhfuil Indeirm Phrognóiseach Idirnáisiúnta acu.
SHANGHAI, CHINA, 10 Deireadh Fómhair, 2022 - D'fhógair JW Therapeutics (HKEX: 2126), cuideachta biteicneolaíochta neamhspleách agus nuálaíoch a dhíríonn ar fhorbairt, déantúsaíocht, agus tráchtálú táirgí imdhíonteiripe cille, go bhfuil an Na.
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
Samhain 2022: Tá an meascán de doxorubicin, vincristine, etoposide, prednisone, agus cyclophosphamide le brentuximab vedotin (Adcetris, Seagen, Inc.) ceadaithe ag an Riarachán Bia agus Drugaí le húsáid i leanaí agus.